Intradiscal rhGDF-5

Phase 2Small molecule

DDePuy Spine

Intradiscal rhGDF-5 is one of 2 small molecule programs targeting Lumbar Disc Degeneration. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lumbar Disc DegenerationActive, not recruiting

Lumbar Disc DegenerationPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Lumbar Disc Degeneration

#DrugCompanyPhaseTrials

Tymlos

RRadius Health, Inc.

Phase 2

1 2

Intradiscal rhGDF-5

DDePuy Spine

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lumbar Disc Degeneration3 trials

A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration

Completed·DDePuy Spine·Phase 1/2·NCT01158924·40 enrolled

A Multicenter, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of 2 Doses of Intradiscal rhGDF-5 (Single Administration) for the Treatment of Early Stage Lumbar Disc Degeneration

Completed·DDePuy Spine·Phase 2·NCT01124006·24 enrolled

A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration

Completed·DDePuy Spine·Phase 1/2·NCT01182337·31 enrolled

Clinical Trial1 trial

Intradiscal rhGDF-5 Phase I/II Clinical Trial

Completed·DDePuy Spine·Phase 1/2·NCT00813813·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Intradiscal rhGDF-5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intradiscal rhGDF-5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intradiscal rhGDF-5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — DePuy Spine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDePuy Spine

Intradiscal rhGDF-5

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lumbar Disc Degeneration3 trials

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News